Intraoperative local fibrinolysis as emergency therapy after early coronary artery bypass thrombosis

European Journal of Cardio-thoracic Surgery

Volumn 15, Issue 3, 1999, Pages 266-270

  Breuer, Martin ^a   Schütz, Albert ^a   Gansera, Brigitte ^a   Eichinger, Walter ^a   Weingartner, Josef ^a   Kemkes, Bernhard ^a  

^a KLINIKUM BOGENHAUSEN   (Germany)

Author keywords

Alteplase; Bypass thrombosis; Cardiac surgery; Fibinolytics; Intraoperative application

Indexed keywords

ALTEPLASE;

ARTICLE; CARDIOGENIC SHOCK; CLINICAL ARTICLE; CORONARY ARTERY BYPASS GRAFT; CORONARY ARTERY THROMBOSIS; DRUG ACTIVITY; DRUG EFFECT; FEMALE; FIBRINOLYSIS; FIBRINOLYTIC THERAPY; GRAFT OCCLUSION; HEART INFARCTION; HEART MUSCLE BLOOD FLOW; HEART MUSCLE NECROSIS; HEART MUSCLE PERFUSION; HUMAN; MALE; POSTOPERATIVE THROMBOSIS; PRIORITY JOURNAL; SURGICAL MORTALITY;

AGED; CORONARY ARTERY BYPASS; CREATINE KINASE; FEMALE; FIBRINOLYTIC AGENTS; GRAFT OCCLUSION, VASCULAR; HUMANS; INTRAOPERATIVE PERIOD; ISOENZYMES; MALE; MIDDLE AGED; RECOMBINANT PROTEINS; REOPERATION; RETROSPECTIVE STUDIES; THROMBOLYTIC THERAPY; TISSUE PLASMINOGEN ACTIVATOR; TREATMENT OUTCOME;

EID: 0344507138     PISSN: 10107940     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1010-7940(99)00010-X     Document Type: Article

References (18)

1. Ivert T., Welti R., Eketrom S., Bjork V. Early mortality after 2902 coronary artery bypass operations. Scand J Thorac Cardiovasc Surg. 23:1989;3-8.
2. Backman C., Jacobsson K., Linderholm H., Osterman G. Comparison of some criteria for diagnosing a myocardial infarction after aorto-coronary bypass grafting (CABG). Clin Physiol. 15:1995;307-317.
3. Matsuwaka R., Sakakibara T., Shintani H., Yagura A., Masai T., Mirayama A., Kodama K. Emergency cardiopulmonary bypass support in patients with severe cardiogenic shock after acute myocardial infarction. Heart Vessels. 11:1996;27-29.
4. Gulba D., Bode C., Runge M., Huber K., Roque M. Thrombolytic agents - an overview. Ann Hematol. 73(Suppl.):1996;9-27.
5. Roque M., Sanz G. Treatment of cardiogenic shock with thrombolysis and coronary angioplasty. Rev Esp Cardiol. 45(Suppl. 2):1992;43-49.
6. Barbash G., White H., Modan M., Diaz R., Hampton J., Heikkila J., Kristinsson A., Moulopoulos S., Paolasso E., Van der Werf T. Outcome of thrombolytic therapy in relation to hospital size and invasive services. The investigators of the international Tissue Plasminogen Activator/Streptokinase Mortality Trial. Arch Int Med. 154:1994;2237-2242.
7. Smalling R., Bode C., Kalbfleisch J., Sen S., Limboug P., Forcky F., Habib G., Feldman R., Hohnloser S., Seals A. More rapid complete and stable coronary artery thrombolysis with bolus administration of reteplase compared with alteplase infusion in acute MI. Circulation. 91:1995;2725-2732.
8. Prewitt R., Schick U., Ducas J. Optimizing coronary artery thrombolysis with i.v. administration of recombinant tissue plasminogen activator. Single bolus vs. double bolus vs. front-loading. Chest. 109:1996;510-515.
9. Mc Neill A., Dickey W., Campbell N., Khan M., Patterson G., Webb S., Adgey A. One-year follow-up after recombinant tissue plasminogen activator administered to patients with acute myocardial infraction. Eur Heart J. 12:1991;624-629.
10. GUSTO Angiographic Investigators The effects of tissue plasminogen activator, streptokinase, or both on coronary-artery patency, ventricular function and survival after acute myocardial infarction. New Engl J Med. 329:1993;1615-1622.
11. Van de Werf F., Wilcox R., Barbash G. In-hospital mortality and clinical course of 20 891 patients with suspected acute myocardial infarction randomized between alteplase and streptokinase with or without heparin. Lancet. 336:1990;71-75.
12. Bode C., Smalling R., Berg G., Burnett G., Lorch G., Kalbfleisch J., Chernoff R., Christie L., Feldman R., Seals A., Weaver W. Randomized comparison of coronary thrombolysis achieved with double-bolus reteplase and front loaded, accelerated alteplase in patients with acute myocardial infarction. The RAPID II investigators. Circulation. 94:1996;891-898.
13. Chandler W. The effects of CPB on fibrin formation and lysis: is a normal fibrinolytic response essential? J Cardiovasc Pharmacol. 27:1996;63-68.
14. Neuhaus K., Essen R., Tebbe U., Vogt A., Roth M., Riess M., Niederer W., Forycki F., Wirtzfeld A., Mäurer W., Limbourg P., Merx W., Haerten K. Improved thrombolysis in acute myocardial infarction with front-loaded administration of alteplase: results of the rt-PA-APSAC patency study. J Am Coll Cardiol. 19:1992;885-891.
15. Heiligenhaus A., Schilling H., Schilling M., Mellin K. Treatment with tissue plasminogen activator (tPA) in risk patients with fibrin reactions after cataract operations. Ophalmologe. 93:1996;49-53.
16. Muller-Lung U., Heindel W., Gawenda M., Lachner K. Local fibrinolytic therapy of arterial occlusions of the lower extremity: initial success and clinical outcome. Aktuelle Radiol. 6:1996;325-329.
17. Vitale N., Renzulli A., Cerasuolo F., Caruso A., Festa M., De Luca L., Cotrufo M. Prosthetic valve obstruction: thrombolysis versus operation. Ann Thorac Surg. 57:1994;365-370.
18. Stock K., Jacob A., Schnabel K. Massive pulmonary embolism: treatment with fragmentation and local fibrinolysis with recombinant human-tissue plasminogen activator. Cardiovasc Intervent Radiol. 20:1997;364-368.